Is it Time to Exit ADMA Biologics Stock After a 22% Monthly Plunge?
ADMA shares plunge after the company cuts 2026 guidance, citing pricing pressure, rising competition and elevated IG channel inventories.
More News
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Wall Street Zen Downgrades Grifols (NASDAQ:GRFS) to Hold
Wall Street Zen cut shares of Grifols from a "buy" rating to a "hold" rating in a research report on Saturday...
Grifols (GRFS) to Release Earnings on Thursday
Grifols (NASDAQ:GRFS) will be releasing its Q1 2026 earnings on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-grifols-sa-stock...
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
ADMA banks on surging Asceniv demand to sustain growth, supported by expanded plasma supply and broader coverage, which should drive continued gains into 2026.
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
ADMA stock slides after a short report sparks volatility, but management pushes back, citing strong Asceniv demand and steady fundamentals.
Grifols, S.A. (NASDAQ:GRFS) Short Interest Update
Grifols, S.A. (NASDAQ:GRFS - Get Free Report) was the target of a significant drop in short interest in March. As of March 31st, there was short interest totaling 5,261,576 shares, a drop of 25.0...
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
ADMA stock plunges after a short report, but strong Asceniv demand, rising revenues, and margin expansion signal potential recovery ahead.
Is ADMA Poised for Margin Growth and Supply Expansion in 2026?
ADMA rides on margin gains, supply deals, and IVIG shift into 2026, but valuation and recent stock decline add complexity for investors.
Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?
ADMA rides on surging Asceniv demand, expanding payer coverage, and stronger plasma supply deals to drive rapid revenue growth through 2027.